Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

47.60 -0.16 (-0.34%)
Streaming Delayed Price Updated: 11:45 AM EDT, May 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Validating headline phrasing and editorial resonance A Director Cashes In Near the Top, but What Remains Matters ↗
This rare disease therapeutics specialist reported a notable insider sale amid a year of strong share price gains and pipeline progress. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Travere Therapeutics Analysts Increase Their Forecasts Following Q1 Earnings ↗
Travere Therapeutics (NASDAQ:TVTX) reported a profit in Q1, surpassing analyst estimates. Shares fell 1.1% on Tuesday, analysts have raised price targets. 
Via Benzinga
News headline image
Travere (TVTX) Q1 2026 Earnings Transcript ↗
Travere (TVTX) Q1 2026 Earnings Transcript 
Via The Motley Fool
Travere Therapeutics (NASDAQ:TVTX) Q1 2026 Results Show Record FILSPARI Sales and FSGS Approval, but Revenue and EPS Miss Estimates ↗
Via Chartmill
Travere Therapeutics (NASDAQ:TVTX) Posts Q4 Earnings Beat on Profitability Despite Revenue Miss ↗
Via Chartmill
Topics Earnings
Why Did TVTX Stock Crash 30% In Pre-Market Today? ↗
Via Stocktwits
Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Technical and Fundamental Momentum for Growth Investors ↗
Via Chartmill
News headline image
Travere (TVTX) Q2 2025 Earnings Transcript ↗
Travere (TVTX) Q2 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Travere (TVTX) Q4 2025 Earnings Transcript ↗
Travere (TVTX) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Travere Therapeutics Director Trims Stake Amid 168% Run, But Is FILSPARI's Revenue Story Just Getting Started? ↗
Focused on rare disease therapies, this biotech firm reported a notable insider sale amid a year of substantial share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
These stocks are moving in today's session ↗
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Topics Artificial Intelligence
News headline image
Tuesday's session: gap up and gap down stocks ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Wondering what's happening in Tuesday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
Biogen's $5.6 Billion Acquisition of Apellis: A Strategic Pivot into Rare Kidney Diseases
In a move that signals a decisive shift away from its traditional focus on neuroscience, Biogen (NASDAQ: BIIB) announced today, March 31, 2026, that it has entered into a definitive agreement to... 
Via MarketMinute
News headline image
Vertex Pharmaceuticals Surges as Breakthrough Kidney Data Sets New Gold Standard for IgA Nephropathy
Shares of Vertex Pharmaceuticals (Nasdaq: VRTX) climbed more than 8% today, reaching a record high as the biotechnology giant unveiled spectacular interim results from its pivotal Phase 3 RAINIER... 
Via MarketMinute
News headline image
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗
Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗
This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗
Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors. 
Via The Motley Fool
News headline image
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs. 
Via The Motley Fool
News headline image
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗
This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments. 
Via The Motley Fool
News headline image
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗
This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments. 
Via The Motley Fool
News headline image
Why Travere Therapeutics Stock Got Trounced on Tuesday ↗
A regulatory decision on a top investigational drug won't be coming as soon as hoped. 
Via The Motley Fool
News headline image
Travere Therapeutics Shares Fall After FDA Extends Filspari Review for FSGS
On January 13, 2026, Travere Therapeutics (NASDAQ: TVTX) faced a sharp reversal of fortune as the U.S. Food and Drug Administration (FDA) announced a three-month extension for its review of Filspari... 
Via MarketMinute
News headline image
Travere Therapeutics Stock Slumps After FDA Extends Drug Review Timeline To April ↗
According to Travere, Filspari would be the first medication indicated for focal segmental glomerulosclerosis if approved. 
Via Stocktwits
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
These stocks are gapping in today's session ↗
Via Chartmill
These stocks that are showing activity before the opening bell on Tuesday. ↗
Via Chartmill
News headline image
Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday ↗
Two analysts waxed bullish on the future of the company. 
Via The Motley Fool
News headline image
Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Momentum and Technical Setup for Growth Investors ↗
Travere Therapeutics (TVTX) shows strong earnings momentum, a bullish technical uptrend, and a current consolidation phase, presenting a potential breakout setup for growth investors. 
Via Chartmill
News headline image
Travere Therapeutics Inc (NASDAQ:TVTX) Screened as a High Growth Momentum Stock with Strong Technical Setup ↗
Travere Therapeutics (TVTX) shows strong high-growth momentum with surging sales and a positive technical setup, signaling a potential breakout. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.